- Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026
- Lead clinical candidate IND filing in Acumen’s EBDTM (enhanced brain delivery) program targeted for mid-2027
- Cash, cash equivalents and marketable securities of
$128.4 million as ofMar. 31, 2026 , expected to support current clinical and operational activities into early 2027 - Company to host conference call and webcast today at 8:00 a.m. ET
“In the first quarter of 2026
Anticipated Milestones
- The Company currently expects to exercise its option to license two compounds developed as part of its collaboration with JCR Pharmaceuticals during the second quarter of 2026.
- The Company expects topline results from ALTITUDE-AD in late 2026. ALTITUDE-AD is a Phase 2 study to investigate sabirnetug for the treatment of early Alzheimer’s disease.
- Topline results are expected to include the difference after 18 months as measured by iADRS (Integrated Alzheimer’s Disease Rating Scale), our primary clinical efficacy endpoint, as well as key secondary endpoints, such as CDR-SB (Clinical Dementia Rating – Sum of the Boxes), certain safety measures such as adverse event rates, including ARIA rates, and key biomarkers.
- The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027.
First Quarter 2026 Financial Results
- Cash Balance. As of
Mar. 31, 2026 , cash, cash equivalents and marketable securities totaled$128.4 million compared to cash, cash equivalents and marketable securities of$116.9 million as ofDec. 31, 2025 . The increase in cash is related to the private placement announced inMarch 2026 that resulted in gross proceeds of$35.75 million . Cash is expected to support current clinical and operational activities into early 2027.
- Research and Development (R&D) Expenses. R&D expenses were
$16.5 million for the quarter endedMar. 31, 2026 , compared to$25.3 million for the quarter endedMar. 31, 2025 . The decrease was primarily due to a reduction in manufacturing and materials costs as well as a reduction in CRO costs associated with our ALTITUDE-AD clinical trial which completed enrollment inMarch 2025 .
- General and Administrative (G&A) Expenses. G&A expenses were
$4.7 million for the quarter endedMar. 31, 2026 , compared to$5.1 million for the quarter endedMar. 31, 2025 . The decrease was primarily due to reductions in legal fees, as well as reductions in accounting, consulting and insurance expenses.
- Loss from Operations. Loss from operations was
$21.1 million for the quarter endedMar. 31, 2026 , compared to$30.4 million for the quarter endedMar. 31, 2025 . This decrease was due to the decreased R&D expenses over the prior year period.
- Net Loss. Net loss was
$20.7 million for the quarter endedMar. 31, 2026 , compared to$28.8 million for the quarter endedMar. 31, 2025 .
Conference Call Details
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Sabirnetug (ACU193)
Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AßOs), which are a highly toxic and pathogenic form of Aß, relative to Aß monomers and amyloid plaques. Soluble AßOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AßOs, sabirnetug aims to address the hypothesis that soluble AßOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the
About ALTITUDE-AD (Phase 2)
Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.?Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen’s business, and Acumen’s ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), including against other antibodies, the timing of the exercise of its option to license up to two candidates in its EBD program, the timing of anticipated topline results of ALTITUDE-AD, Acumen’s plans to develop a candidate to treat Alzheimer's Disease utilizing EBD technology, including its expectations with respect to timing for the submission of an IND, as well as its potential for developing a best-in-class therapeutic candidate for people living with Alzheimer’s Disease. These statements are based upon the current beliefs and expectations of
CONTACTS:
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@icrhealthcare.com
| Condensed Balance Sheets | ||||||||
| (in thousands, except share and per share data) | ||||||||
| 2026 | 2025 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 51,796 | $ | 53,989 | ||||
| Marketable securities, short-term | 76,602 | 62,876 | ||||||
| Prepaid expenses and other current assets | 4,696 | 5,387 | ||||||
| Total current assets | 133,094 | 122,252 | ||||||
| Restricted cash | 231 | 231 | ||||||
| Other assets, long-term | 304 | 350 | ||||||
| Total assets | $ | 133,629 | $ | 122,833 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,655 | $ | 554 | ||||
| Accrued clinical trial expenses | 8,183 | 10,616 | ||||||
| Accrued expenses and other current liabilities | 5,268 | 10,072 | ||||||
| Debt, short-term | 14,123 | 8,765 | ||||||
| Total current liabilities | 29,229 | 30,007 | ||||||
| Debt, long-term | 16,924 | 22,396 | ||||||
| Total liabilities | 46,153 | 52,403 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, | - | - | ||||||
| Common stock, | 7 | 6 | ||||||
| Additional paid-in capital | 554,647 | 516,803 | ||||||
| Accumulated deficit | (467,199 | ) | (446,462 | ) | ||||
| Accumulated other comprehensive income | 21 | 83 | ||||||
| Total stockholders' equity | 87,476 | 70,430 | ||||||
| Total liabilities and stockholders' equity | $ | 133,629 | $ | 122,833 | ||||
| Condensed Statements of Operations and Comprehensive Loss | ||||||||
| (in thousands, except share and per share data) | ||||||||
| (unaudited) | ||||||||
| Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses | ||||||||
| Research and development | $ | 16,484 | $ | 25,266 | ||||
| General and administrative | 4,665 | 5,104 | ||||||
| Total operating expenses | 21,149 | 30,370 | ||||||
| Loss from operations | (21,149 | ) | (30,370 | ) | ||||
| Other income (expense) | ||||||||
| Interest income | 1,064 | 2,471 | ||||||
| Interest expense | (1,069 | ) | (1,023 | ) | ||||
| Change in fair value of embedded derivatives | 460 | 190 | ||||||
| Other expense, net | (43 | ) | (64 | ) | ||||
| Total other income | 412 | 1,574 | ||||||
| Net loss | (20,737 | ) | (28,796 | ) | ||||
| Other comprehensive gain (loss) | ||||||||
| Unrealized (loss) gain on marketable securities | (62 | ) | 63 | |||||
| Comprehensive loss | $ | (20,799 | ) | $ | (28,733 | ) | ||
| Net loss per common share, basic and diluted | $ | (0.33 | ) | $ | (0.48 | ) | ||
| Weighted-average shares outstanding, basic and diluted | 63,219,289 | 60,525,628 | ||||||
| Statements of Cash Flows | ||||||||
| (in thousands) | ||||||||
| (unaudited) | ||||||||
| Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (20,737 | ) | $ | (28,796 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 12 | 15 | ||||||
| Stock-based compensation expense | 2,396 | 2,474 | ||||||
| Amortization of premiums and accretion of discounts on marketable securities, net | 25 | (588 | ) | |||||
| Change in fair value of embedded derivatives | (460 | ) | (190 | ) | ||||
| Amortization of right-of-use asset | 34 | 30 | ||||||
| Realized gain on marketable securities | (6 | ) | (3 | ) | ||||
| Noncash interest expense | 346 | 299 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | 691 | 950 | ||||||
| Other long-term assets | - | 16 | ||||||
| Accounts payable | 1,047 | (4,592 | ) | |||||
| Accrued clinical trial expenses | (2,433 | ) | (3,796 | ) | ||||
| Accrued expenses and other liabilities | (5,043 | ) | 60 | |||||
| Net cash used in operating activities | (24,128 | ) | (34,121 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchases of marketable securities | (40,823 | ) | (35,048 | ) | ||||
| Proceeds from maturities and sales of marketable securities | 27,016 | 63,816 | ||||||
| Purchases of property and equipment | - | (79 | ) | |||||
| Net cash (used in) provided by investing activities | (13,807 | ) | 28,689 | |||||
| Cash flows from financing activities | ||||||||
| Proceeds from private placement, net of offering costs | 35,746 | - | ||||||
| Proceeds from exercise of stock options | 145 | 37 | ||||||
| Repurchase of common shares to pay employee withholding taxes | (149 | ) | (73 | ) | ||||
| Net cash provided by (used in) financing activities | 35,742 | (36 | ) | |||||
| Net change in cash and cash equivalents and restricted cash | (2,193 | ) | (5,468 | ) | ||||
| Cash and cash equivalents and restricted cash at the beginning of the period | 54,220 | 35,859 | ||||||
| Cash and cash equivalents and restricted cash at the end of the period | $ | 52,027 | $ | 30,391 | ||||
